New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

Asklepios Kliniken · ISIN: DE000A0ETLQ3 · EQS - Company News (29 News)
Country: Germany · Primary market: Germany · EQS NID: 1143692
28 October 2020 05:55PM

Asklepios successfully issues Schuldschein loan agreement worth EUR 730 million


DGAP-News: Asklepios Kliniken / Key word(s): Financing
Asklepios successfully issues Schuldschein loan agreement worth EUR 730 million

28.10.2020 / 17:55
The issuer is solely responsible for the content of this announcement.


Asklepios successfully issues Schuldschein loan agreement worth EUR 730 million

  • Multiple oversubscription: original issue volume of EUR 200 million increased to EUR 730 million
  • Continued strong interest from national and international investors in the megatrend of health

Hamburg, 28 October 2020. Asklepios Kliniken GmbH & Co. KGaA has successfully placed a Schuldschein loan agreement worth EUR 730 million on the market. Due to high demand, the transaction was oversubscribed several times over and the original target volume of EUR 200 million was increased significantly. The placement is thus one of the biggest transactions on the Schuldschein market so far this year.

The issue forms part of Asklepios's long-term financing strategy, which is particularly geared towards ensuring the security and availability of financing by means of a balanced medium- to long-term maturity profile and financial flexibility while also optimising the costs of capital. A large part of the funds generated will be used for the early repayment of the acquisition financing that Asklepios had borrowed in connection with the RHÖN-KLINIKUM AG transaction.

"During the first wave of infections in the COVID-19 pandemic, the Schuldschein market was temporarily considerably subdued. As the markets then thawed, we seized the opportunity to bring a relatively large Schuldschein loan agreement onto the market," says Hafid Rifi, CFO of the Asklepios Group. "With terms of 5 to 20 years and an average duration of 7.2 years, we have also achieved a very good, long-term result."

Since 2010, Asklepios has been increasingly involving the capital market in its corporate financing, and it enjoys a good reputation among investors in Germany and abroad as a long-standing issuer.

"We are delighted with the high demand from both existing investors and new investors, which demonstrates that Asklepios represents an attractive investment opportunity," comments Benedikt Brörmann, Manager of Corporate Finance at Asklepios. "This is also shown by the share of the issue volume attributable to international investors, which came to around 45% and was thus higher than in any of our previous Schuldschein transactions."

The placement of the Schuldschein loan agreement was managed by Bayerische Landesbank, BNP Paribas, Commerzbank Aktiengesellschaft, DZ BANK AG and Landesbank Hessen-Thüringen Girozentrale as the joint lead arrangers.

About Asklepios

Asklepios Kliniken is one of the leading private operators of hospitals and healthcare facilities in Germany. The hospital group stands for highly qualified care for its patients, with a clear commitment to medical quality, innovation and social responsibility. On this basis, Asklepios has grown dynamically since it was founded almost 35 years ago. The Group currently has around 160 healthcare facilities throughout Germany, including acute care hospitals for all levels of care, specialist clinics, psychiatric and forensic facilities, rehabilitation clinics, nursing homes and medical service centres. In the 2019 financial year, 2.5 million patients were treated at the Asklepios Group's facilities. The company has more than 49,000 employees.

IR contact
Mirjam Constantin
Investor Relations
Asklepios Kliniken GmbH & Co. KGaA
Debusweg 3
61462 Königstein-Falkenstein
Tel: +49 61 74 90-1166
Fax: +49 61 74 90-1110
ir@asklepios.com

PR contact:
Rune Hoffmann
Head of Corporate Communications & Marketing
Asklepios Kliniken GmbH & Co. KGaA
Rübenkamp 226
22307 Hamburg
Tel.: +49 40 1818-82 6630
Fax: +49 40 1818-82 6639
presse@asklepios.com

Visit Asklepios online, on Facebook or on YouTube:
www.asklepios.com
www.asklepios.com/ir
www.facebook.com/asklepioskliniken
www.youtube.com/asklepioskliniken "



28.10.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


1143692  28.10.2020 

fncls.ssp?fn=show_t_gif&application_id=1143692&application_name=news&site_id=boersengefluester_html

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.